Pyxis Oncology (NASDAQ: PYXS) shares Q2 2025 quarterly results update

Rhea-AI Filing Summary

Pyxis Oncology, Inc. furnished an update on its business by issuing a press release with its financial results for the quarter ended June 30, 2025 and a broader corporate update. The company submitted this information in a current report so investors can access the press release, which is attached as Exhibit 99.1. The report clarifies that the press release and related information are being furnished, not filed, which limits certain legal liabilities and means the material is not automatically incorporated into other regulatory documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000178222300017822232025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Pyxis Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40881	83-1160910
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
321 Harrison Avenue
Boston, Massachusetts				02118
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 453-3596

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		PYXS		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the Quarter ended June 30, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
Exhibit No.		Description
99.1		Press Release dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Pyxis Oncology, Inc.
Date:	August 14, 2025	By:	/s/ Jitendra Wadhane
			Jitendra Wadhane Principal Financial and Accounting Officer

FAQ

What did Pyxis Oncology (PYXS) disclose in this 8-K filing?

Pyxis Oncology furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update, attaching the release as Exhibit 99.1.

Which period do the Pyxis Oncology (PYXS) results in this update cover?

The financial results discussed in the furnished press release cover the quarter ended June 30, 2025.

How did Pyxis Oncology (PYXS) provide its Q2 2025 results to investors?

The company issued a press release containing its quarterly results and corporate update, and furnished that press release as Exhibit 99.1 to this current report.

Is the Pyxis Oncology (PYXS) press release considered filed with the SEC?

The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Who signed this Pyxis Oncology (PYXS) 8-K report?

The report was signed on behalf of Pyxis Oncology, Inc. by Jitendra Wadhane, the Principal Financial and Accounting Officer.

What exhibits are attached to this Pyxis Oncology (PYXS) 8-K?

The filing lists Exhibit 99.1, the press release dated August 14, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.